AcelRx’s Pain Drug Zalviso Delayed By Delivery Device Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.
You may also be interested in...
AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems
FDA asked for clinical study before reviewing data AcelRx generated after previous ‘complete response,’ CEO King said.
AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems
FDA asked for clinical study before reviewing data AcelRx generated after previous ‘complete response,’ CEO King said.
AcelRx Tries Transparency To Reassure Investors After Zalviso ‘Complete Response’
Trying to beat The Medicines Co. to market with a patient-administered post-surgical pain analgesic, AcelRx hopes it can refile the NDA for Zalviso by the end of 2014, based on already-filed amendments and adjustments to the delivery mechanism and instructions for use.